Rapamycin with antiretroviral therapy in AIDS-associated kaposi sarcoma: An AIDS malignancy consortium study

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 5, 2012, Pages 447-454

  Krown, Susan E ^a   Roy, Debasmita ^b,j   Lee, Jeannette Y ^c   Dezube, Bruce J ^d   Reid, Erin G ^e   Venkataramanan, Raman ^f,g   Han, Kelong ^f,i   Cesarman, Ethel ^h   Dittmer, Dirk P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ GENENTECH INC   (United States)

^j NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

AIDS; Kaposi sarcoma; MTOR; Pharmacokinetic interactions; Rapamycin

Indexed keywords

ALPHA INTERFERON; ATAZANAVIR PLUS RITONAVIR; BLEOMYCIN; DOXORUBICIN; EFAVIRENZ; HALOFUGINONE; IMATINIB; INCYCLINIDE; INTERLEUKIN 6; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; OGLUFANIDE; PACLITAXEL; PROTEIN KINASE B; PROTEIN S6; RAPAMYCIN; VASCULOTROPIN; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG SAFETY; ENZYME PHOSPHORYLATION; FEMALE; HERPES VIRUS; HUMAN; HUMAN TISSUE; KAPOSI SARCOMA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN BIOPSY; VIRUS LOAD;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, VIRAL; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; SARCOMA, KAPOSI; SIROLIMUS; TUMOR MARKERS, BIOLOGICAL; VIRAL LOAD;

EID: 84859759200     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31823e7884     Document Type: Article

References (38)

1. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356: 2271-2281. (Pubitemid 46849157)
2. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256-4265.
3. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009; 27:3822-3829.
4. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28:69-76.
5. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753-762.
6. Jain AK, Venkataramanan R, Fridell JA, et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl. 2002;8:838-840. (Pubitemid 35012296)
7. Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int. 2005;67:1622-1629. (Pubitemid 40463144)
8. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharma-cokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007;7:2816-2820. (Pubitemid 350045781)
9. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994; 266:1865-1869.
10. Sawyers CL. Will mTOR inhibitors make it as cancer drugs? Cancer Cell. 2003;4:343-348. (Pubitemid 37491095)
11. Sodhi A, Chaisuparat R, Hu J, et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell. 2006;10:133-143. (Pubitemid 44175903)
12. Tomlinson CC, Damania B. The K1 protein of Kaposi's sarcoma-associated herpesvirus activates the Akt signaling pathway. J Virol. 2004;78:1918-1927. (Pubitemid 38176723)
13. Sin SH, Roy D, Wang L, et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood. 2007;109:2165-2173. (Pubitemid 46348219)
14. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347-5356. (Pubitemid 46206988)
15. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med. 2005;352:1317-1323. (Pubitemid 40411498)
16. Chaisuparat R, Hu J, Jham BC, et al. Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma. Cancer Res. 2008;68:8361-8368.
17. Barozzi P, Riva G, Vallerini D, et al. Indirect antitumor effects of mammalian target of rapamycin inhibitors against Kaposi sarcoma in transplant patients. Transplantation. 2009;88:597-598.
18. Kuhn JG, Chang SM, Wen PY, et al. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007;13:7401-7406.
19. Ware N, MacPhee IA. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation. Curr Opin Mol Ther. 2010;12:270-283.
20. Heredia A, Amoroso A, Davis C, et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci USA. 2003;100:10411-10416. (Pubitemid 37071892)
21. Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol. 2008;26:1027-1032.
22. Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol. 2002;20: 153-159. (Pubitemid 34032606)
23. Dittmer DP. Transcription profile of Kaposi's sarcoma-associated her-pesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays. Cancer Res. 2003;63:2010-2015. (Pubitemid 36538598)
24. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2011;117:1089-1096.
25. Simard EP, Pfeiffer RM, Engels EA. Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med. 2010;170:1337-1345.
26. Mosam A, Aboobaker J, Shaik F. Kaposi's sarcoma in sub-Saharan Africa: a current perspective. Curr Opin Infect Dis. 2010;23:119-123.
27. Nguyen HQ, Magaret AS, Kitahata MM, et al. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS. 2008;22:937-945. (Pubitemid 351652244)
28. WHO, UNAIDS, UNICEF. Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Geneva, Switzerland: World Health Organization; 2010.
29. Krown SE, Lee JY, Dittmer DP. More on HIV-associated Kaposi's sarcoma. N Engl J Med. 2008;358:535-536; author reply 536.
30. Roy D, Dittmer DP. Phosphatase and tensin homolog (PTEN) on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma. Am J Pathol. 2011;179:2108-2119.
31. Roy J, Paquette JS, Fortin JF, et al. The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother. 2002;46:3447-3455. (Pubitemid 35192910)
32. Ikezoe T, Hisatake Y, Takeuchi T, et al. HIV-1 protease inhibitor, rito-navir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res. 2004;64:7426-7431. (Pubitemid 39372084)
33. Inaba T, Fischer NE, Riddick DS, et al. HIV protease inhibitors, saqui-navir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. Toxicol Lett. 1997;93:215-219. (Pubitemid 28055525)
34. Knox TA, Oleson L, von Moltke LL, et al. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr. 2008;49:358-368.
35. Oostendorp RL, Huitema A, Rosing H, et al. Coadministration of rito-navir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clin Cancer Res. 2009;15:4228-4233.
36. Schmitt C, Hofmann C, Riek M, et al. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Pharmacotherapy. 2009;29:1175-1181.
37. Jayakanthan M, Chandrasekar S, Muthukumaran J, et al. Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS. J Mol Graph Model. 2010;28:455-463.
38. Bernstein WB, Dennis PA. Repositioning HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS. 2008;3:666-675.